Anthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’
Anthropic board director Vas Narasimhan is betting that AI can help Novartis overcome biological latency in drug development.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Coverage from Fierce Biotech reports that Vas Narasimhan, who serves as a director on Anthropic's board, is betting that artificial intelligence can help Novartis solve what he calls biological latency. The same coverage frames this as part of a broader Big Pharma push into AI-driven drug discovery. Reuters coverage from November 19, 2026, reports that Big Pharma, with an eye on Anthropic, says AI is shrinking drug discovery timelines, positioning the AI company as a reference point for pharmaceutical industry strategy. STAT's Pharmalittle column, also dated November 19, 2026, includes AI speeding drug development among the industry stories it is tracking alongside Sanofi's reported interest in Insmed. Pfizer published its own piece on the same date, titled Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer, detailing how the company is applying artificial intelligence within its research and development operations. Healthcare Today contributed a comment piece on the same day examining how AI can help the pharmaceutical industry more broadly. The coverage does not yet specify the exact mechanisms Narasimhan envisions for addressing biological latency, nor does it quantify the timeline reductions being claimed across the industry. What the coverage establishes is that multiple pharmaceutical companies are publicly aligning their R&D strategies with AI capabilities, with Anthropic emerging as a named reference point in that conversation. The background context is that drug discovery has traditionally operated on long timelines constrained by the pace of biological experimentation and validation, a constraint that industry leaders now describe as addressable through machine learning and large language models. What to watch next, based only on stated facts, is whether Novartis and other pharmaceutical companies disclose specific AI partnerships, clinical candidates accelerated by these methods, or measurable changes to discovery timelines that can be independently verified.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 3h ago.
Quick answers
Who is Vas Narasimhan?
Coverage identifies him as a board director at Anthropic and connects him to Novartis.
What is biological latency?
The coverage uses the term but does not define it.
Which outlets covered this trend?
Fierce Biotech, Reuters, STAT, Pfizer, and Healthcare Today.
What is Pfizer's position on AI in R&D?
Pfizer published a piece describing how AI is reshaping its research and development.
Coverage (5)
- Pharmalittle: We're reading about Sanofi eyeing Insmed, AI speeding drug development, and more STAT · 1d ago
- Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer Pfizer · 1d ago
- Comment: How AI can help the pharmaceutical industry Healthcare Today · 1d ago
- Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines Reuters · 1d ago
- Anthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’ Fierce Biotech · 1d ago
Topics
Related trends
Goldman Says Stock Selloff Has Legs as Panic Index Nears Maximum
Goldman Sachs warns of further stock selling after its panic gauge climbed near its maximum level.
Anthropic staffer claims solution to mathematics’ Riemann hypothesis
An Anthropic employee has reportedly claimed a solution to the 167-year-old Riemann Hypothesis, one of mathematics' most famous unsolved problems.
Anthropic mathematician claims to have solved prestigious Millennium Prize problem with Claude
Anthropic mathematician Levent Alpöge claims he proved the Riemann hypothesis with Claude, one of seven Millennium Prize problems carrying a $1 million prize.
Claude is cracking down on abusive users
Anthropic tightens Claude usage policies as new research links abusive prompts to degraded AI performance across platforms.
Cathie Wood’s ARK Invest was a big buyer of Anthropic as she tells CNBC she’s ‘quite optimistic’
Cathie Wood's ARK Invest bought $90 million in Anthropic shares while selling Nvidia and adjusting crypto assets.
Stocks slide despite Anthropic’s record debut and Trump touts ‘unbelievable’ China summit: Morning Rundown
Global markets react as Anthropic launches a record-breaking IPO alongside high-stakes geopolitical summits.